降低58.4斤！替尔泊肽减重效果超越胃部切除手术

Core Viewpoint - Tirzepatide has shown significant weight loss results in clinical trials, demonstrating its potential as an effective treatment for obesity and type 2 diabetes [4][6][9]. Group 1: Clinical Trial Results - The SURMOUNT-3 study reported an average weight loss of 21.1% at 72 weeks for patients treated with tirzepatide, with a total average weight loss of 26.6% (29.2 kg) at 84 weeks, compared to only 3.8% (4.1 kg) in the placebo group [9]. - In the SURMOUNT-CN trial, patients receiving 10 mg and 15 mg of tirzepatide experienced weight reductions of 14.4% and 19.9% respectively at 52 weeks, significantly outperforming the placebo group [10]. - The proportion of patients losing at least 5% of their body weight was 91.4% and 92.7% for the 10 mg and 15 mg groups, respectively, compared to 29.4% in the placebo group [10]. Group 2: Safety Profile - The overall safety profile of tirzepatide in the SURMOUNT studies was consistent with previous research, with the most common adverse effects being gastrointestinal in nature, mostly mild to moderate [9][11]. Group 3: Comparison with Surgical Options - Tirzepatide's weight loss efficacy is comparable to that of bariatric surgery, which has an average weight loss rate of 25.2% after one year for sleeve gastrectomy, the most common metabolic surgery [12].